The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Phase II Results for Pembrolizumab Monotherapy in Metastatic TNBC

Sylvia Adams, MD
Published Online:7:24 PM, Tue June 20, 2017

Sylvia Adams, MD, associate professor, Department of Medicine, NYU Langone Medical Center, discusses phase II results from cohort A of the KEYNOTE-086 trial, which explored pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.